Figure 3.
Mechanism of the anticancer effects of CsDNVs. (A) STAT3 and (B) p-STAT3 expression in A549 cells treated with CsDNVs was analyzed by WB. (C) Relative protein levels of STAT3 and p-STAT3 in A549 cells treated with CsDNVs were analyzed by Image Lab software. *p < 0.05, ***p < 0.001 vs control group. N=3. (D) STAT3 and (E) p-STAT3 expression level of A549 cells treated with CuB was analyzed by WB. (F) The relative protein level of STAT3 and p-STAT3 in A549 cells treated with CuB was analyzed by Image Lab software. **p < 0.01, ***p < 0.001 vs control group. N=3. The cell cycle distribution of A549 cells treated with (G) PBS and (H) CsDNVs was analyzed by flow cytometry. (I) Intracellular ROS levels in A549 cells treated with CuB or CsDNVs were observed by fluorescence microscopy. Scale bar: 100 μm. (J) Quantification of ROS level in A549 cells. *p < 0.05, ***p < 0.001 vs Blank group. N=3. (K) Caspase-9 and (L) caspase-3 activities of A549 cells treated with PBS or CsDNVs were measured by a microplate reader. ***p < 0.001. N=3.